Updated: FDA rejects higher dose of Regeneron's Eylea after inspection at contractor Catalent
Regeneron’s new 8 mg version of its blockbuster drug Eylea was rejected by the FDA because of an ongoing review of inspection findings at the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
